WOOJUNG BIO EGM Approves Name Change and Business Diversification with Limited Share Price Impact

WOOJUNG BIO held an extraordinary general meeting on July 8, 2026, and approved all agenda items including a company name change and expansion of business objectives as originally proposed. The record date was June 15, 2026.
Only 39.7% of total voting shares were represented, but all votes were in favor, indicating low shareholder interest but no procedural issues.
Eight new business objectives were added covering cosmetics raw materials, pharmaceutical intermediates, animal health products, and more, signaling a strategic diversification.
Ham Seok-hee was appointed as a new inside director for a three-year term. No capital changes or financing were involved, so no dilution risk for existing shareholders.
[AI Summary]WOOJUNG BIO formalized business diversification through the EGM without any capital change, making it neutral for the stock price. The low shareholder turnout suggests limited retail interest; future business performance will be the key driver.